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Abstract
Bovine lactoferrin C-lobe is able to prevent both influenza virus hemagglutination and cell infection. In particular, it was 
demonstrated that the fragment 418SKHSSLDCVLRP429 is a potent antiviral peptide. Therefore, we tried to increase the 
stability of this fragment through side-chain lactam cyclization of the peptide, S[KHSSLD]CVLRP (1). However, classic 
strategy involving solid-supported cyclization of the linear precursor, containing orthogonal allyl/alloc-based protection 
for the key amino and carboxyl residues, did not provide the desired cyclic peptide. Here, we report the identification of 
problematic stretches during the sequence assembly process and the optimization of the different parameters involved in the 
construction of 1. Results indicated a significant influence of β-protecting group of both aspartic acid and adjacent cysteine 
residues on the formation of side products. Therefore, the identification of suitable β-protecting groups of these residues 
allowed us to optimize the synthesis of designed lactam-bridged cyclic peptide.
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Introduction
Bovine lactoferrin (bLf) has a broad anti-influenza activ-
ity (Lönnerdal 1995; Van der Strate 2001). In particular, 
it was demonstrated that bLf C-lobe (418–429) fragment, 
1SKHSSLDCVLRP12, is able to inhibit virus hemaggluti-
nation and infection of all major virus subtypes, including 
H1N1 and H3N2, at pico- to femto-molar concentration 
range (Ammendolia 2012). NMR conformational analysis 
of this fragment has highlighted global turn conformation, 
encompassing four β-turns (type IV) and a γ-turn structure 
(Scala 2017).
Accordingly, the stabilization of the peptide conformation 
by, for example, the cyclization of linear compounds can be 
considered a valid approach to the identification of more 
stable and selective compounds (Mosberg 1999; Camarero 
2001; Davies 2003).
As evident from Fig. 1 (Scala 2017), the three β-turns 
formed by residues 2–5, 4–7, and 6–9, in the reference pep-
tide, could be further stabilized through the formation of a 
side-chain lactam bridge between  Lys2 and  Asp7 residues 
(Ser-[Lys-His-Ser-Ser-Leu-Asp]-Cys-Val-Leu-Arg-Pro, 1).
Side-chain lactam bridges linking separated amino acids 
that are spaced 4–7 residues apart in the linear sequence 
offer a convenient and flexible method for introducing con-
formational constraints or for improving the metabolic sta-
bility of a peptide (Houston 1995; Taylor 2002).
Solid-phase peptide synthesis (SPPS) is a convenient 
approach to prepare this type of constrained cyclic peptide 
(White 2011). In general, its preparation by Fmoc solid-
phase methods requires a pair of selectively cleavable pro-
tecting groups on the amine and carboxylic acid side chains 
to be linked (Taylor 2002). Among these protecting groups, 
the Allyl ester (OAll) for carboxylic acid side chain along 
with its urethane-based partner for amine side chains, the 
Alloc group, are the most used. After linear assembly of 
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the full sequence, the OAll and Alloc groups are removed 
according to well-known protocols and the cyclization is car-
ried out (Grieco 2001). However, this well-accepted protocol 
to the formation of side-chain lactam led to a major product 
with a mass difference of + 27 with respect to expected pep-
tide, corresponding to piperidinyl adducts. This paper details 
the identification and quantification of the side products and 
their formation mechanisms, as well as the analysis of reac-
tion conditions and optimization of a new protocol for the 
synthesis of the desired product.
Materials and methods
Chemicals
Nα-Fmoc-protected amino acids (Fmoc, fluorenylmeth-
oxycarbonyl), Fmoc-Rink-amide-AM resin, 2-chloro-
trityl-chloride resin, N-hydroxy-benzotriazole (HOBt), 
2-(1H-benzotriazole-1-yl)-1,1,3,3-tetramethyluronium 
hexafluoro-phosphate (HBTU), N,N-diisopropylethyl-amine 
(DIEA), piperidine, morpholine, piperazine, triisopropylsi-
lane (TIS), and trifluoroacetic acid (TFA) were purchased 
from Iris Biotech (Germany). Fmoc-PAL-PEG-PS resin 
(Applied Biosystems) was purchased from Thermo Fis-
cher Scientific (Italy). Peptide synthesis solvents, as well 
as  CH3CN for high-performance liquid chromatography 
(HPLC) were reagent grade and were acquired from com-
mercial sources and used without further purification unless 
otherwise noted.
Peptide synthesis
Method A: (peptide 2, peptides 7–14). The synthesis of pep-
tides was performed according to the solid-phase approach 
using standard Fmoc methodology in a manual reaction ves-
sel (Stewart 1984; Atherton 1989).
The first amino acid was linked on Fmoc-Rink-amide 
resin (100–200 mesh, 1% DVB, 0.59 mmol/g) or Fmoc-
PAL-PEG-PS resin (100–200 mesh, 1% DVB, 0.22 mmol/g) 
previously deprotected by a 25% piperidine solution in N, 
N-dimethylformamide (DMF, 5 min and 30 min).
The following protected amino acids were then added 
stepwise:  Nα-Fmoc-Pro-OH,  Nα-Fmoc-Arg(Pbf)-OH, 
 N α - F m o c - L e u - O H ,   N α - F m o c - V a l - O H , 
 Nα-Fmoc-Cys(Trt)-OH or  Nα-Fmoc-Cys(tBu)-OH, 
 Nα-Fmoc-Asp(OAll)-OH or  Nα-Fmoc-Asp(ODmab)-OH or 
 Nα-Fmoc-Asp(OtBu)-OH or  Nα-Fmoc-Asp(2-PhiPr)-OH, 
 N α - F m o c - A l a - O H ,   N α - F m o c - L e u - O H , 
 N α-Fmoc-Ser( tBu)-OH,   Nα-Fmoc-His(Tr t ) -OH, 
 Nα-Fmoc-Lys(All)-OH or  Nα-Fmoc-Lys(Mmt)-OH.
Each coupling reaction was accomplished using a three-
fold excess of amino acid with HBTU and HOBt in the 
presence of DIEA (6 equiv). The peptide resin was washed 
with dichloromethane (DCM, 3×, DMF (3×) and DCM (3×) 
and the Fmoc deprotection protocol, described above, was 
repeated after each coupling step. The Fmoc removal was 
accomplished by treating the protected peptide resin with 
a 25% solution of piperidine in DMF (5 min and 25 min) 
or 25% piperazine/DMF, 25% morpholine/DMF, and 25% 
piperidine/DMF + 0.1 M HOBt (as shown in Table 1). In 
addition, after each step of deprotection and after each cou-
pling step, Kaiser test was performed to confirm the com-
plete removal of the Fmoc protecting group and to verify 
that complete coupling has occurred on all the free amines 
on the resin. After peptide assembling, the N-terminal Fmoc 
group was removed. After peptide assembling, the N-termi-
nal Fmoc group was removed and peptides were released 
from the resin using a cleavage mixture containing 90% 
TFA, 5% TIS, and 5%  H2O for 3 h. The resin was removed 
Fig. 1  NMR-derived structures of C-lobe (418–429) fragment (left) and the designed lactam peptide structure (1, right)
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by filtration, and the crude peptide was recovered by pre-
cipitation with cold anhydrous ethyl ether to give a white 
powder and then lyophilized.
Method B: (peptide 2 on 2-Chlorotrityl-chloride resin). 
Peptide was synthesized using a 2-chlorotrityl-chloride 
resin (100–200 mesh, 1.8 mmol/g). The first amino acid, 
 Nα-Fmoc-Pro-OH (3 equiv relative to resin capacity) was 
dissolved in dry DCM (approximately 10 mL per gram of 
resin). A small amount of DMF may be needed to achieve 
complete dissolution. This solution was added to the resin 
followed by 12 equiv (relative to resin capacity) of DIEA. 
The mixture was agitated for 60 min, and then, the resin 
was washed with (17/2/1) DCM/Methanol/DIEA (3×), DCM 
(× 3), DMF (2×), and DCM (2×). Successively, Fmoc pro-
tective group was removed and synthesis was accomplished 
as previously described.
Synthesis of lactam peptide 1: the correspond-
ing linear peptide was synthesized as described above 
and the amino acids  Nα-Fmoc-Asp(2-PhiPr)-OH and 
 Nα-Fmoc-Lys(Mmt)-OH were used as lactam precursors. 
After linear assembly, the 2-PhiPr and Mmt groups were 
removed according to the following procedure: 200 mg of 
peptide resin was washed with dichloromethane (DCM) and 
a solution of 1% TFA/DCM was added. The reaction was 
allowed to proceed for 30 min. The peptide resin was washed 
with DCM (3×), DMF (3×), and DCM (4×). The macrocy-
clic lactam ring formation was mediated by the addition of 
HBTU (6 equiv), HOBt (6 equiv), and DIEA (12 equiv) for 
2 h. The reaction was carried out under an inert atmosphere 
to avoid the oxidation of thiol group of cysteine. The pro-
cess was repeated if necessary (Kaiser test used to monitor 
completion).
The N-terminal Fmoc group was removed as described 
above. Finally, the peptides were released from the resin 
with TFA/TIS/H2O (90:5:5) for 3 h. The resin was removed 
by filtration, and the crude peptide was recovered by pre-
cipitation with cold anhydrous ethyl ether to give a white 
powder and then lyophilized.
Purification and characterization
All crude peptides were purified by RP-HPLC on a prepara-
tive C18-bonded silica column (Phenomenex Kinetex AXIA 
100 Å, 100 × 21.2 mm, 5 µm) using a Shimadzu SPD 20A 
UV/VIS detector, with detection at 220 and 254 nm. The 
column was perfused at a flow rate of 15 mL/min with a 
linear gradients of  CH3CN (0.1% TFA) in water (0.1% TFA), 
from 5 to 90% over 20 min. Analytical purity and retention 
time (tr) of each peptide were determined using analytical 
HPLC performed on a Supelco, Ascentis express peptide 
C18 column (50 × 3.00 mm, 2.7 μm) with a flow rate of 
0.800 mL/min using linear gradients of  CH3CN (0.1% TFA) 
in water (0.1% TFA), from 5 to 90% over 9 min.
All analogues showed > 97% purity when monitored at 
220 nm. Homogeneous fractions, as established using ana-
lytical HPLC, were pooled and lyophilized. Peptides molec-
ular weights were determined by ESI mass spectrometry and 
LC–MS in an LC–MS 2010 instrument fitted with Phenom-
enex, Ascentis express peptide C18 column (50 × 3.00 mm, 
2.7 µm), eluted with a linear gradient from 5 to 90% B over 
9 min, at a flow rate of 0.600 mL/min. Electro-spray ioniza-
tion mass spectrometry (ESI–MS) analysis in positive ion 
mode was made using a Finnigan LCQ Deca ion trap instru-
ment, manufactured by Thermo Finnigan (San Jose, CA, 
USA), equipped with the Excalibur software for processing 
the data acquired. The sample was dissolved in a mixture of 
water and methanol (50/50) and injected directly into the 
electro-spray source, using a syringe pump, which maintains 
constant flow at 5 mL/min. The temperature of the capillary 
was set at 220 °C.
Results and discussion
Sequence assembly of the lactam peptide Ser-c[Lys-His-
Ser-Ser-Leu-Asp]-Cys-Val-Leu-Arg-Pro, 1 was performed 
with standard Fmoc peptide synthesis using α-allyl-
protected aspartic acid residue on a rink-amide resin. 
Unfortunately, this approach failed completely. Therefore, 
we studied the stepwise elongation of the peptide and we 
observed the formation of side products for the first time 
after the Aspartic acid Fmoc deprotection with piperidine 
(25% v/v in DMF, 30 min). In fact, LC–MS analysis of 
the sequence H-Asp(OAll)-Cys-Val-Leu-Arg-Pro-NH2 (2) 
revealed the formation of three compounds: desired com-
pound (2), aspartimide (3), and piperidinyl derivative(s) 
(4) (Fig. 2).
Table 1  Influence of the solid support and base on the amount of by-
products formed during the synthesis of Asp(OAll)-Cys-Val-Leu-Arg-
Pro
a All by-products were formed in quantitative yield after 3  h base 
treatment
Entries Type of resin Fmoc deprotection
(for 5 + 25 min)
By-producta
a Rink amide 25% piperidine/DMF 4




d Rink amide 25% Piperazine/DMF 5
e Rink amide 25% Morpholine/
DMF
6
f Rink amide 25% piperidine/
DMF + HOBt 0.1 M
4
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According to the literature (Dölling 1994; Yang 1994; 
Mergler 2003), our results could be interpreted as a spon-
taneous removal of allyl group from aspartic acid side 
chain, assuming an aspartimide formation followed by 
aminolysis with piperidine (Fig. 3). The reaction involves 
the nucleophilic attack of the nitrogen atom attached 
to the α-carboxylic group to the side-chain carboxyl 
group of aspartic acid. Subsequent nucleophilic attack of 
piperidine to the imide ring results in the formation of α- and 
β-piperidides. NMR analysis in  DMSOd6 solution clearly 
demonstrated the presence of two peptides which differed 
for the presence of an allyl or a piperidinyl (pip) group on 
the Asp residue (see supporting info). Considering the two 
possible α- or β-piperidides, relatively intense NOE correla-
tions peaks between the signals of Hβ protons of Asp and Hα 
proton of Cys, and between the Hα proton of Asp and the 
Fig. 2  LC-MS analysis of 
crude peptide DCVLRP, after 
cleavage with TFA/TES/
H2O (90:5:5 v/v, rt. 1.5 h), 
revealed the formation of 
three compounds: (2) desired 
product (calc. m/z = 743); 
(3) aspartimide-containing 
product (calc. m/z = 683); (4) 
piperidide-containing product 
(calc. m/z = 769). HPLC condi-
tions: RP-C18, 5–90%  CH3CN 
in 0.1% TFA over 9 min, 
0.6 ml min−1
Fig. 3  Formation of side products. a Piperidine (25% v/v in DMF). b TFA/TES/H2O (90:5:5 v/v, rt. 1.5 h)
Investigation on side-product formation during the synthesis of a lactoferrin-derived…
1 3
piperidine proton signals (Fig. S1) demonstrate the presence 
of the α-piperidide by-product, while the β-isomer was not 
observed. Electron withdrawing effect of the terminal amine 
group on the α-carbonyl can explain the selective attack of 
the piperidine nitrogen on this group.
To minimize the aspartimide-related by-product forma-
tion, we studied the influence of resins, protecting groups, 
bases, and amino acid sequence on the side-product forma-
tion. To simulate deprotection conditions of prolonged syn-
thesis, all peptides were incubated with piperidine (25%v/v 
in DMF) for 30 min, 1, 2, 3, 6, 12, and 16 h (Dölling 1994; 
Lauer 1995).
Factors influencing by‑product formation
Solid support
It has been observed that the aspartimide impurity forma-
tion is also dependent on the polymeric support (Lukszo 
1996; Subirόs-Funosas 2011). Use of resin linkers such as 
Fmoc-PAL-PEG-PS helps to reduce the amount of second-
ary products. In this resin, chains of polyethylene glycol are 
grafted with the result that they move away from the func-
tional groups of the resin core; hence, the reaction conditions 
become more “solution-like” (Forns and Fields 2000). It is 
also reported that the use of 2-chlorotrityl-chloride resin, 
which offers the possibility of mild acidolysis of the pep-
tide chain, prevents this undesired cyclization (Ruczynski 
2008; Dixon D2009). However, in our case, the uses of both 
solid supports were not successful (Table 1, entries b and c, 
respectively).
Base
The type of the secondary amine used in the Fmoc deprotec-
tion protocol also affects both the amount and the ratio of 
by-products (Dölling 1994; Yang 1994). Thus, we replaced 
the piperidine (pKa = 11.12) with the milder base pipera-
zine (pKa = 9.73) and morpholine (pKa = 8.3), which could 
reduce aspartimide formation, even at the cost of the reac-
tion rate. As observed in Table 1, the use of these bases was 
ineffective with the prevailing formation of side products, 
piperazine (Fig. 4, compound 5, Table 1, entry d) and mor-
pholine (Fig. 4 compound 6, Table 1, entry e) derivatives.
The addition of N-hydroxylamine-based derivative, 
as hydroxybenzotriazole (HOBt), contributes to the wide 
arsenal of approaches to prevent the formation of aspartim-
ide and derived by-products (Flora 2005; Michels 2012). 
The abstraction of the amide backbone proton has been 
proposed as the crucial step in the cyclization that leads to 
aspartimide. Thus, the addition of relative strong acid HOBt 
results in competition with the Asp-X amide backbone for 
the base present in the medium (Scheme 1). The effect of the 
HOBt should be the decrease of the percentage of negatively 
charged amide backbone nitrogen, which is responsible for 
initiating aspartimide derivative formation.
Fig. 4  Piperazine (5) and 
morpholine (6) derivatives 
formation
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However, in our case, the addition of HOBt to piperidine 
solution (0.1 M) did not avoid the formation of piperidinyl 
derivative (Table 1, entry f).
Sequence
The nature of the neighboring amino acid located at the 
C-terminus of the aspartic acid (Asp-X) and the amino 
acidic sequence can influence the aspartimide formation 
(Lauer 1995).
Initially, we decided to check the contribution of each 
residue to the by-product formation through an alanine scan-
ning analysis (peptides 7–11, Table 2). As described above, 
all peptides were synthesized on a rink-amide resin using 
allyl as aspartic acid protecting group and were incubated 
with piperidine at different times. As shown in Table 2, these 
changes did not show a significant effect to suppress aspar-
timide formation resulting, after 16 h piperidine treatment, 
in the formation of the piperidinyl adducts.
In addition to evaluate if the specific sequence, rather 
than the amino acid composition, is critical for by-product 
formation, we synthesized three scramble peptides (12–14, 
Table 2). These peptides, containing the three aliphatic 
residues of the original sequence (Ile, Val, and Pro) con-
tiguous to the aspartic residue, could provide a steric and 
conformational impairment to the initial nucleophilic attack 
of the nitrogen atom to the side-chain carboxyl group of 
aspartic acid. As shown in Table 2, in these cases, the forma-
tion of side products was not observed (see supporting info), 
indicating that the conversion of Asp into aspartimide units 
could be conformation-dependent.
β‑Carboxyl protecting group
Other influential factor in the formation of aspartimide-
based side compounds is the nature of the β-carboxyl pro-
tecting group of Asp (Subirόs-Funosas 2011). Thus, we ana-
lyzed the comportment of three Asp β- protecting group: two 
highly sterically hindered ODmab [4-{N-[1-(4,4-dimethyl-
2,6-dioxocyclohexylidene)-3-methylbutyl] amino}benzyl] 
and 2-PhiPr (β-(2-phenylisopropyl) and the bulky but less 
voluminous tert-butyl group (Fig. 5).
As shown in Table 3, the β-protection of Asp as ODmab 
(Table 3, entry a) does not result in improved prevention 
of the side reactions and the results are comparable to 
that achieved by β-allyl ester protection (Table 1, entry a). 
The use of bulky tert-butyl (Table 3, entry b) and 2-PhiPr 
(Table 3, entries b and c, respectively) groups has shown 
greater efficacy than the above-mentioned protection strate-
gies in preventing this side reaction in basic media. In fact, 
for entry b (Table 3), we have not observed the formation of 
aspartimide and piperidinyl derivatives that are formed in 
very small amounts for entry c (Table 3).
As above described we also assessed the influence of the 
protecting group on the side chain of the adjacent amino 
acid on the nucleophilic attack initiated by amide backbone 
nitrogen atom, using tert-butyl group and 2-PhiPr as protec-
tor groups of Cys and Asp, respectively (Table 3, entry d). 
In this case, this orthogonal protection increased the for-
mation of side products. These results indicate a possible 
electronic interaction between the aromatic ring of Trt and 
2-PhiPr favoring a steric hindrance able to avoid the initial 
aspartimide formation (Fig. 6).
Although the use of the tBu protecting group on the 
aspartic acid residue gave better results, this does not give us 
the possibility to have an orthogonal protection, so we car-
ried out the synthesis of our linear peptide on a Rink-amide 
Scheme 1  Competition between 
N-hydroxylamine and amide 
backbone proton abstraction
Table 2  Formation of piperdinyl derivatives during the synthesis of 
peptides 7–14 
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resin using the amino acids  Nα-Fmoc-Asp(2-PhiPr)-OH and 
 Nα-Fmoc-Lys(Mmt)-OH as lactam precursors. After linear 
assembly, the 2-PhiPr and the Mmt groups were removed 
and the macrocyclic lactam ring formation was mediated. 
In these conditions, the peptide yield was 30%.
Conclusion
The synthesis of the lactam-bridged peptide, S[KHSSLD]
CVLRP proved to be difficult yielding by-products such 
as aspartimide and α-piperidinyl derivatives according to 
LC–MS and NMR analyses.
Fig. 5  Structure of Asp 
β-carboxyl protecting groups 
used in this work
Table 3  Influence of β-carboxyl 
protecting group on by-product 
formation





Type of resin Fmoc deprotection (for 
5 + 25 min)
By-product
a ODmab Trt Rink amide 25% piperidine/DMF +++
b OtBu Trt Rink amide 25% piperidine/DMF −
c O2-PhiPr Trt Rink amide 25% piperidine/DMF +
d O2-PhiPr tBu Rink amide 25% piperidine/DMF +++
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A systematic study clearly revealed that the conformation 
adopted from the precursor peptide (DCVLRP) promotes 
the formation of these undesired by-products. Moreover, we 
also observed a strong influence of the side-chain protecting 
group nature of the neighboring aspartic and cysteine amino 
acids on the initial cyclization process. Use of Asp(tBu) and 
Cys(Trt) avoided the by-product generation, even if this pro-
tocol was not suitable for our synthetic approach.
The most effective orthogonal strategy for minimization 
of aspartimide formation during the synthesis of the lactam-
bridged peptide, S[KHSSLD]CVLRP was (i) 2-PhiPr side-
chain protection of aspartate; (ii) Trt side-chain protection 
of cysteine; and (iii) 4-methoxytrityl for lysine side chain.
Our results indicate that the aspartimide formation 
depends not only on the nature of the neighboring amino 
acid located at the C-terminus of the aspartic acid but also 
on the protecting groups used and on the conformation 
adopted by the peptide backbone.
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